Arrowhead Wins EU Approval for REDEMPLO® in Rare Lipid Disease
PASADENA, Calif., June 22, 2026 Arrowhead Pharmaceuticals has reached a major regulatory milestone after the European Commission (EC) granted...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Eli Lilly FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology oncology innovation Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine targeted therapy
PASADENA, Calif., June 22, 2026 Arrowhead Pharmaceuticals has reached a major regulatory milestone after the European Commission (EC) granted...
LONDON, June 25, 2026 Evaluate, a Norstella company and a leading provider of pharmaceutical market intelligence, has been recognized...
